The key catalyst is the 12-month topline data from the PRECISE-AD Phase 1b trial expected in early 2027. Monitor for any data readouts or regulatory updates between now and then. The upcoming conferences may provide management commentary on trial progress but are unlikely to move the stock materially on their own.
Price Chart
Executive Summary
ProMIS Neurosciences announced its participation in five investor conferences in September 2026, including a fireside chat at the Cantor Global Healthcare Conference and presentations at the H.C. Wainwright and Roth conferences. The company also noted that 12-month topline data from its PRECISE-AD Phase 1b trial is anticipated in early 2027, following blinded 6-month interim data reported in July 2026. This is a routine corporate update with no new clinical or financial data, but the upcoming data catalyst in early 2027 is the key event to watch.
Key Facts
- ProMIS will present at five investor conferences in September 2026, including Cantor, Moody Capital, H.C. Wainwright, Nasdaq Tower event, and Roth Healthcare.
- 12-month topline data from the PRECISE-AD Phase 1b trial in early Alzheimer's disease is anticipated in early 2027.
- Blinded 6-month interim data from the fully enrolled Phase 1b trial was reported in July 2026.
- No new financial, clinical, or regulatory data were disclosed in this press release.
Financial Impact
No financial impact from this announcement; the press release is a routine conference participation update.
Risk Factors
- Phase 1b trial data may fail to show sufficient efficacy or safety, leading to a significant stock decline.
- The company is a clinical-stage biotech with no approved products, relying on successful trial outcomes and financing.
- High cash burn rate without disclosed revenue may require future dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 3 | $9.12 $9.15 | ▲ +0.33% | ▲ +0.75% | $9.68 (+6.14%) |
Oct 6, 2026 21d ago | Press Release | $9.21 $9.12 | ▼ −0.98% | ▼ −0.74% | $9.68 (+5.10%) |
Sep 1, 2026 8w ago | Press Release | $13.35 $13.98 | ▲ +4.68% | ▲ +4.24% | $9.68 (−27.49%) |
Jul 14, 2026 15w ago | Press Release | $13.66 $14.01 | ▲ +2.53% | ▲ +2.13% | $9.68 (−29.14%) |
May 28, 2026 21w ago | Press Release | $10.87 $10.81 | ▼ −0.55% | ▼ −0.79% | $9.68 (−10.95%) |
May 12, 2026 24w ago | 8-K | $10.49 $10.57 | ▲ +0.76% | ▲ +0.19% | $9.68 (−7.72%) |
Apr 3, 2026 29w ago | EFFECT | $10.96 $10.88 | ▲ +0.73% | ▲ +0.79% | $9.68 (+11.68%) |
Mar 25, 2026 30w ago | S-3 | $15.13 $14.74 | ▲ +2.58% | ▲ +0.90% | $9.68 (+36.02%) |
Mar 18, 2026 31w ago | S-3 | $18.21 $17.60 | ▲ +3.35% | ▲ +1.61% | $9.68 (+46.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers